title: Multiple Sclerosis-related Uveitis: Does MS Treatment Affect Uveitis Course?
abstract: OBJECTIVE
  Few data are available regarding the optimal treatment of multiple sclerosis (MS)-related uveitis. The aim of this study was to describe clinical features of MS-associated uveitis and determine how MS treatment affects the course of uveitis.
  
  
  METHODS
  Retrospective, multicenter study. Patients were divided into two groups according to the use (group 2) or not (group 1) of immunomodulatory drugs. Characteristics of uveitis and treatment were reviewed.
  
  
  RESULTS
  A total of 68 eyes from 36 patients (17 in group 1 and 19 in group 2) were included. All patients were treated with topical and/or systemic steroids for uveitis. Uveitis occurred 1-17 years prior to neurologic symptoms in 78% of patients. Uveitis was more severe in group 2 (p<0.05), with a tendency toward a higher rate of chronic uveitis (p = 0.06).
  
  
  CONCLUSIONS
  MS-related uveitis has often a favorable evolution. Patients on interferon-beta have more severe and chronic uveitis. As far as we are concerned, interferon-beta given on the sole indication of uveitis is not recommended. If steroid-sparing agent is required for intraocular inflammation, immunosuppressive drugs should be considered.
authors.affiliation: a Ophthalmology Department , Centre Hospitalier National des Quinze-Vingt , Paris , France.
authors.forename: Léa
authors.initials: L
authors.lastname: Jouve
authors.affiliation: b Internal Medicine Department , Centre Hospitalier National des Quinze-Vingt , Paris , France.
authors.forename: Rabah
authors.initials: R
authors.lastname: Benrabah
authors.affiliation: b Internal Medicine Department , Centre Hospitalier National des Quinze-Vingt , Paris , France.
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Héron
authors.affiliation: c Ophthalmology Department , DHU VIewMaintain, Piti-Salpêtrière Hospital , Paris , France.
authors.forename: Bahram
authors.initials: B
authors.lastname: Bodaghi
authors.affiliation: c Ophthalmology Department , DHU VIewMaintain, Piti-Salpêtrière Hospital , Paris , France.
authors.forename: Phuc
authors.initials: P
authors.lastname: Le Hoang
authors.affiliation: c Ophthalmology Department , DHU VIewMaintain, Piti-Salpêtrière Hospital , Paris , France.
authors.forename: Valérie
authors.initials: V
authors.lastname: Touitou
mesh_terms: D060433:Administration, Ophthalmic; D000328:Adult; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D009883:Ophthalmic Solutions; D012189:Retrospective Studies; D014605:Uveitis / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D014792:Visual Acuity
chemical_list: D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D009883:Ophthalmic Solutions
keywords: Corticosteroids; cystoid macular edema; immunosuppressive drugs; interferon-beta; relapsing-remitting MS; uveitis